- Home
- Gufic Biosciences eyes to grab major share of Rs 3000 crore lyophilized antibiotics antifungal market in India
Gufic Biosciences eyes to grab major share of Rs 3000 crore lyophilized antibiotics antifungal market in India
Gufic Biosciences has launched New Drug Delivery System: Dual Chamber Bags at affordable price first time in India, and it aims to capture a dominant share of the high demand in this particular segment.
by Prashant Kapadia/NHN
Mumbai, 6th March 2022: Gufic Biosciences Ltd, a fast-growing pharmaceutical player recognized for its innovative, high-quality pharmaceutical and herbal products and has targeted to capture major share of Rs 3000 crore lyophilized antibiotics antifungal market in India. Known for its Innovative and High Quality Pharmaceutical and Herbal Products along with a wide range of APIs, Gufic Biosciences has launched New Drug Delivery System: Dual Chamber Bags at affordable price first time in India.
Contributing immensely to the government’s ambitious Make in India drive Gufic Biosciences has collaborated with its French counterpart to manufacture this new technology indigenously in India. Until now the dual chamber bags have been largely imported and used to cost very high to the patients. On the contrary, Gufic Biosciences has not only launched high-quality Dual Chamber Bags at an affordable and pocket friendly price, these New Drug Delivery System products have even longer shelf -life.
Dr. Debesh Das, COO, Gufic Biosciences Limited said, “We are committed to reduce the country’s dependency on imported products especially in critical care segment. Moving ahead with this vision we have launched indigenously produced Dual Chamber Bags of global standards in India at a pocket-friendly price. As we are experiencing rapidly growing demand for our product we look forward to grab major market share in this particular segment.”
These Dual Chamber Bags launched by Gufic Biosciences are 2-Chamber IV Bags made up of polypropylene (DEHP free) with a peelable aluminium foil allowing the storage of unstable drugs which need a reconstitution just before the administration to the patient. The peelable seal separates lyophilized (or powder) drug and its diluent. Moreover, the product complies with the US and EU pharmacopoeias and it is manufactured in ISO7 clean room under cGMP.
Features and benefits of Dual Chamber Bags (DCB) by Gufic Biosciences:
.It reduces risk of bloodstream infections and thereby ensures Patient’s safety.
.Stability of the drug is much more in DCB rather than vials as it provides complete protection from light & moisture
.The bag’s closed system ensures that the product is sterile and avoids risks of contamination during handling.
.No Nitosamines used- No risk of Cancer in diverse organs and tissues.
.DCB, tubing & twist-off port are DEHP free- No risk of Cancer, birth defects & other reproductive harms.
.Glue free-Eradicates the risk of interaction with drug product.
.Prefilled with intended dosage and diluent in 2 separte bags- Accurate dosing, easy handling, seal integrity and high stability
.Individualized treatment regimens-Avoids hospital contamination & provides high stability and convenience- Thus significantly improving product quality & patient compliance.
.Provides high stability- Avoids leachability, free of airborne bacterial contaminants & needle stick injuries.
One of the most important USPs of these ready-to-use Dual Chamber Bags by Gufic Biosciences is that they prevent contamination and protects the potency and efficacy of the drug. These bags also offer ease of handling at the time of reconstitution and also help in avoiding the dilution errors since the drug is present with the exact required quantity of the diluent to be used. It can be reconstituted just before administration by simply peeling off the aluminium foil and folding & squeezing the bag, thus the diluent enters the drug chamber and mixes with the drug. It is then directly administered as IV infusion to the patient with the help of IV tubes.
Recognised as one of the largest manufacturers of Lyophilized injections in India, Gufic Biosciences has a fully automated lyophilization plant. The company’s lyophillized product portfolio includes Antibiotic, Antifungal, Cardiac, Infertility, Antiviral and proton-pump inhibitor segments, among others. Its products are supplied to all the major hospital chains and leading medical facilities.
About Gufic Biosciences Ltd : Founded by Late Shri Pannalal Choksi, Gufic Biosciences Ltd is in the Pharmaceutical industry since 1970, and it’s known and respected for its high-quality standards of its products. Gufic Biosciences is a private limited company listed on Bombay Stock Exchange. Gufic Biosciences offers state of the art contract manufacturing services. Its manufacturing facilities are GMP compliant, technologically advanced, and supported by trained service personnel at all levels. Gufic Biosciences has the capacity to develop and deliver new products and specialized drug delivery systems. It specialises in Lyophilized Products, Critical care medicines and Infertility products among others. Gufic Biosciences has a strong, skilful and experienced R&D team who believe in continuous advancement of its products through innovation. Moreover, the company has an extensive network of representatives promoting these products all across the country.